Kimura Y, Hamamoto K, Furudate M, Fukuda H, Shishido F, Endo K, Yui N, Kusakabe K, Suzuki K, Kawakami K, Ishii K, Koizumi K, Yokoyama K, Hisada K, Nakagawa T, Kasagi K, Konishi J, Ichiya Y, Masuda K, Nakajo M, Kubo A, Torizuka K
Kyoto University.
Kaku Igaku. 1996 Dec;33(12):1347-58.
The phase III clinical trial of strontium-89 chloride agent (SMS.2P) was performed in 90 patients with painful bone metastases secondary to prostate (53), breast (18) and other types of cancer (19). Some patients experienced a transient increase in pain or nausea and vomiting. However both symptoms subsided and serious side effects were not observed in any of the patients. As reported, we confirmed some abnormal changes in peripheral blood picture. A decrease in the number of white blood cells and platelets was considered to be partly a result of bone marrow suppression due to 89Sr irradiation. Pain was substantially improved after 89Sr therapy in 58% of the patients and there was some alleviation in 12%. The release from pain was accompanied by an improved quality of life for these patients including sleep patterns and morbidity. Some patients were able to resume their former life styles. Most of the improved patients experienced pain relief from days to one week following 89Sr therapy and in half cases, this remained effective for 2 or 3 months. There were even cases in which the pain relief continued over an observation period of time of clinical study.
对90例继发于前列腺癌（53例）、乳腺癌（18例）和其他类型癌症（19例）的骨转移疼痛患者进行了氯化锶-89制剂（SMS.2P）的III期临床试验。一些患者出现疼痛短暂加重或恶心呕吐。然而，两种症状均消退，且未在任何患者中观察到严重副作用。如报告所述，我们证实外周血象有一些异常变化。白细胞和血小板数量减少被认为部分是由于89Sr照射导致骨髓抑制的结果。58%的患者在接受89Sr治疗后疼痛得到显著改善，12%的患者有一定程度缓解。疼痛缓解伴随着这些患者生活质量的改善，包括睡眠模式和发病率。一些患者能够恢复以前的生活方式。大多数病情改善的患者在接受89Sr治疗后数天至一周内疼痛缓解，半数病例在2至3个月内仍有效。甚至有病例在临床研究的观察期内疼痛缓解持续存在。
